Sarepta (SRPT) volatility low into shares could have 'considerably more upside,' Barron's says
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Sarepta (SRPT) share price recently doubled after a surprise FDA approval of its Duchenne muscular dystrophy drug Exondys 51, Sarepta could have "considerably more upside" when taking into account traditional biotech valuation metrics, Barron's says. Option implied volatility index mean is at 59, compared to its 52-week range of 67 to 399, according to Livevol.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freeport-McMoran (FCX) call put ratio 3 calls to 1 put as shares rally 4% into Q4
- Caterpillar (CAT) call put ratio 1 call to 1.6 puts into Q4
- Kellogg (K) short duration call active
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!